期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 18, 页码 7617-7635出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01672
关键词
-
资金
- National Natural Science Foundation of China [81273378, 21372261, 81673305, 81602960]
- Jiangsu Province Funds for Distinguished Young Scientists [BK20160033]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Program for New Century Excellent Talents in University [NCET-13-1033]
- Startup Funding for Introduced Talents of Nanjing Medical University [KY109RC1602]
- Jiangsu Shuang Chuang team
The increasing understanding of the role of nitric oxide (NO) in cancer biology has generated significant progress in the use of NO donor-based therapy to fight cancer. These advances strongly suggest the potential adoption of NO donor-based therapy in clinical practice, and this has been supported by several clinical studies in the past decade. In this review, we first highlight several types of important NO donors, including recently developed NO donors bearing a dinitroazetidine skeleton, represented by RRx-001, with potential utility in cancer therapy. Special emphasis is then given to the combination of NO donor(s) with other therapies to achieve synergy and to the hybridization of NO donor(s) with an anticancer drug/agent/fragment to enhance the activity or specificity or to reduce toxicity. In addition, we briefly describe inducible NO synthase gene therapy and nanotechnology, which have recently entered the field of NO donor therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据